Kaitlyn Bader, Senior Editor

From the February cover: Joseph Zabinski, PhD, MEM, and Stefan Weiss, MD, MBA, FAAD, share their expertise into AI’s capabilities in dermatology and specifically, rare diseases such as generalized pustular psoriasis.

Lifileucel is a tumor-derived autologous T cell immunotherapy.

The 2-GEP test is made of 2 biomarkers, LINC00518 and PRAME.

ICYMI, this week we had news about the National Rosacea Society's Seal of Acceptance Program, Dermavant's submitted sNDA for tapinarof cream 1% to treat AD, Galderma's accepted BLA for nemolizumab for the treatment of prurigo nodularis and AD, and more.

New data on the devices will be available at the 2024 American Academy of Dermatology Annual Meeting.

The FDA has also granted nemolizumab Priority Review for prurigo nodularis.

This week’s collection of the latest dermatologic studies covers the causal relationship between lipid-related metabolites and androgenic alopecia, contact allergens in self-tanning products, a retrospective cross-sectional analysis of vitiligo patients in Canada, and combining systemic anti-PD-1 treatment with adjuvant ablative fractional laser in a mouse model of cutaneous SCC.

Tapinarof cream demonstrated highly statistically significant improvement in the primary end point of vIGA-AD treatment success over vehicle at week 8.

Click here to answer this week’s acne poll.

ICYMI, this week we had news about Masterclasses in Dermatology, JNJ-2113's significant PASI and IGA responses for plaque psoriasis, Almirall's partnership with the Centre for Genomic Regulation, and more.

Shanna Miranti, MPAS, PA-C, shares updates on the status of roflumilast foam 0.3% and Cabtreo available in US pharmacies.

Dermatologists Jeanine Downie, DiAnne Davis, and Hope Mitchell reveal the La Roche-Posay products they recommend to patients with dry skin, eczema, and more, at the flagship store in France.

Krystal Biotech’s B-VEC was administered as an eyedrop for a patient with dystrophic epidermolysis bullosa with cicatrizing conjunctivitis.

The guidelines update the American Academy of Dermatology’s 2016 recommendations for acne management in adults, adolescents, and children aged 9 and older.

Ablon’s session highlights include best practices for hair restoration.

Learn more about the in-depth topics covered in the January 2024 print issue of Dermatology Times.

Learn more about the in-depth topics covered in the January 2024 topical treatments for vitiligo supplement of Dermatology Times.

Let us know if you plan to attend IMCAS World Congress 2024.

So far, 2024 is shaping up to be just as busy as 2023 with new dermatology innovations, approvals, and data. Review what's still to come in 2024.

Advancements in assistance from artificial intelligence include ambient listening to take notes during physician and patient conversations.

DermTech’s study results demonstrated that in patients with Fitzpatrick skin types IV-VI, all 3 melanomas diagnosed by histopathology were correctly identified by the 2-GEP assay as positive for LINC00518 and PRAME.

The VISIBLE clinical program will create a longitudinal collection of more than 20,000 clinical images across all skin tones.

ICYMI, this week we had news about Winter Clinical Hawaii data, FDA updates to dupilumab's label to include hand and foot AD involvement, the phase 1 trial of EVO756 for adults with chronic spontaneous urticaria, and more.

The high-concentration and citrate-free biosimilar was first available in a single 40 mg dose.

This week’s collection of the latest dermatologic studies covers the association between smoking and male pattern hair loss, immunohistochemical expression of angiotensin-converting enzyme-2 in the skin of patients with COVID-19, stiff skin syndrome, and pityriasis rosea and pityriasis rosea-like eruption following COVID-19 vaccination.

The pooled analyses from Arcutis’ INTEGUMENT-1 and INTEGUMENT-2 studies were presented at the 2024 Winter Clinical Hawaii Dermatology Conference.

Data from Arcutis’ STRATUM study was presented at the 2024 Winter Clinical Hawaii Dermatology Conference.

The promising results were presented in a poster at the 2024 Winter Clinical Hawaii Dermatology Conference in Honolulu, Hawaii.

Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.

Currently, some United States Pharmacopeia carbomer monographs allow unacceptable levels of benzene